ADA 2014: GSK presents new data for once-weekly Tanzeum in type 2 diabetes

Patients enrolled in of four randomized Phase III studies who remained on Tanzeum/Eperzan (albiglutide), a once-weekly glucagon-like peptide (GLP-1) receptor agonist, continued to show blood glucose lowering at three years, consistent with results at the one year (52 week) primary endpoint, according to new data presented by UK pharma major GlaxoSmithKline (LSE: GSK) at the American Diabetes Association (ADA) in San Francisco.

In the four studies, the primary endpoint of blood glucose lowering, defined as the reduction of HbA1c (glycated hemoglobin, a measure of blood glucose levels) from baseline was assessed at 52 weeks ( results previously announced). Those patients who remained in the study until year three continued to receive randomized treatment, as pre-specified in the study protocol, to further assess the efficacy and safety profile of albiglutide. Safety data for albiglutide in these studies were also consistent with the results observed up to year one. Commonly reported adverse reactions included nausea, diarrhea, and injection site reactions.

Vlad Hogenhuis, senior vice-president and head, Cardiovascular, Metabolic and Neurosciences Franchise, GSK, said: “While many Phase III trials in type 2 diabetes are typically six months in duration, we set out to assess weekly-administered albiglutide for up to three years. We are proud to be able to present these data which further characterize the efficacy and safety profile of albiglutide.”